$GOOGL

Here Are Morgan Stanley's New Top Stock Picks For The Next 12-Months

Morgan Stanley updated its 'Vintage Values' stock picks for 2027, including Alphabet, Coca-Cola, and Apple. The 2026 list gained 32.12%, outperforming the S&P 500. The 2027 portfolio focuses on large-cap growth stocks with high quality metrics. Key selections include Alphabet, Coca-Cola, Apple, Dynatrace, Eli Lilly, and others. GOOGL rose 2%, KO fell 1%, and AAPL added 0.8% on Monday.

Original reporting
Published Sep 21, 2026, 11:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Here Are Morgan Stanley's New Top Stock Picks For The Next 12-Months — source image
Decision brief

The 30-second read

$GOOGLBullishMed
01

Why it matters

The first public disclosure of the list provides fresh guidance for portfolio construction and may drive short‑term buying pressure in the named stocks.

02

Market read

Analyst recommendations from a leading bank can shift short‑term demand for the highlighted equities.

03

What to watch

Potential concentration risk and valuation premium not fully addressed.

Relevance 6/10Novelty 7/10Timing: published Sep 21 2026

Background

Morgan Stanley refreshed its Vintage Values stock picks for the next 12 months, naming 15 equities across tech, consumer, health, and infrastructure.

Company-level read

Ticker impact

$GOOGLBullishMedium confidence
Context

Morgan Stanley added Alphabet to its top‑conviction 12‑month buy list.

Expected impact

potential modest upside on news flow

Evidence & confidence

First‑report of a high‑conviction recommendation from a major bank.

$KOBullishMedium confidence
Context

Coca‑Cola was named a top pick in Morgan Stanley's new Vintage Values list.

Expected impact

limited upside, mainly defensive positioning

Evidence & confidence

First‑report of analyst endorsement.

$AAPLBullishMedium confidence
Context

Apple appears among the 15 equities selected for the 2027 portfolio.

Expected impact

minor supportive effect

Evidence & confidence

Analyst list adds fresh positive bias.

$DTBullishMedium confidence
Context

Dynatrace was listed as a key name in Morgan Stanley's new top‑stock picks.

Expected impact

potential modest rally

Evidence & confidence

First‑report of analyst recommendation.

$LLYBullishMedium confidence
Context

Eli Lilly is part of the 15‑stock Vintage Values 2027 roster.

Expected impact

limited upside

Evidence & confidence

New analyst pick.

$EQIXBullishMedium confidence
Context

Equinix was named in Morgan Stanley's updated 12‑month buy‑and‑hold list.

Expected impact

small supportive effect

Evidence & confidence

First‑report of recommendation.

$HONBullishMedium confidence
Context

Honeywell Aerospace appears among the 15 selected equities.

Expected impact

modest upside potential

Evidence & confidence

New inclusion in a high‑conviction list.

$KEYSBullishMedium confidence
Context

Keysight Technologies is listed as a top pick in the Vintage Values portfolio.

Expected impact

minor upside

Evidence & confidence

First‑report of recommendation.

Market effects

Highlights growth bias toward large‑cap tech and consumer staples, may influence sector rotation.

U.S. equity market focus; limited cross‑regional effect.

Analyst list from a major U.S. bank can affect global investor sentiment on listed names.

Counterpoint

Some investors may view the list as overly bullish on already‑high‑priced mega‑caps.

Key entities

  • Morgan Stanley

    Equity strategists who compiled the Vintage Values list.

Related articles

$LLYHighAI 9/10

TD Cowen reiterates Buy on Eli Lilly stock, $1,250 target on approval

TD Cowen reiterated a Buy rating and $1,250 price target on Eli Lilly (LLY) following the approval of its Inluriyo combination therapy. The firm projects 2026 global sales of $290 million, growing to $1.05 billion by 2032. Other analysts, including Berenberg and Guggenheim, also raised their price targets, citing strong growth prospects. Eli Lilly's market cap is $1.04 trillion, with a 55% return over the past year.

$AAPLMed

Key facts: AAPL Duo ships Oct 23; ~6M y/e, 40% by 2027; Pro delays, costs; 8%/14%

Apple (AAPL) launched the foldable iPhone Duo with a 7.6-inch display, shipping on Oct. 23. Analysts expect ~6M units by year-end and 40% of the foldable market by 2027. iPhone 18 Pro models face production delays and higher component costs. Analysts predict the Duo could make up 8% of units and 14% of iPhone revenue next year. AAPL held $147B in cash at fiscal Q3 end. Investors sued AAPL over Bitcoin losses from fake crypto wallet apps.

$LLYLow

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5B in a Houston manufacturing facility, aiming to boost production of its oral GLP-1 treatment, Foundayo. The project highlights challenges in forecasting demand for breakthrough therapeutics and underscores Houston's growing role as a biomanufacturing hub. The investment is part of a broader trend of U.S. pharma reshoring.